Hologic Valuation

Is HOLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HOLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HOLX ($71.65) is trading below our estimate of fair value ($152.36)

Significantly Below Fair Value: HOLX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HOLX?

Key metric: As HOLX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HOLX. This is calculated by dividing HOLX's market cap by their current earnings.
What is HOLX's PE Ratio?
PE Ratio20.6x
EarningsUS$789.50m
Market CapUS$16.26b

Price to Earnings Ratio vs Peers

How does HOLX's PE Ratio compare to its peers?

The above table shows the PE ratio for HOLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average55.8x
BAX Baxter International
124.5x40.5%US$15.1b
ZBH Zimmer Biomet Holdings
19.7x8.1%US$21.3b
STE STERIS
34.6x11.5%US$20.5b
PODD Insulet
44.4x2.0%US$18.7b
HOLX Hologic
20.6x7.8%US$16.3b

Price-To-Earnings vs Peers: HOLX is good value based on its Price-To-Earnings Ratio (20.6x) compared to the peer average (55.8x).


Price to Earnings Ratio vs Industry

How does HOLX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$8.08m
PAVM PAVmed
0.4x-90.0%US$6.39m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
HOLX 20.6xIndustry Avg. 35.2xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HOLX is good value based on its Price-To-Earnings Ratio (20.6x) compared to the US Medical Equipment industry average (35.2x).


Price to Earnings Ratio vs Fair Ratio

What is HOLX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HOLX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.6x
Fair PE Ratio26.3x

Price-To-Earnings vs Fair Ratio: HOLX is good value based on its Price-To-Earnings Ratio (20.6x) compared to the estimated Fair Price-To-Earnings Ratio (26.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HOLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$71.65
US$85.85
+19.8%
7.9%US$95.00US$70.00n/a17
Dec ’25US$79.50
US$87.22
+9.7%
7.2%US$96.00US$70.00n/a15
Nov ’25US$82.33
US$87.14
+5.8%
7.0%US$96.00US$70.00n/a16
Oct ’25US$80.56
US$86.93
+7.9%
7.9%US$96.00US$70.00n/a15
Sep ’25US$81.24
US$87.07
+7.2%
8.6%US$96.00US$70.00n/a15
Aug ’25US$83.20
US$86.50
+4.0%
8.6%US$96.00US$70.00n/a14
Jul ’25US$74.10
US$85.27
+15.1%
7.6%US$95.00US$70.00n/a15
Jun ’25US$73.78
US$85.14
+15.4%
7.8%US$95.00US$70.00n/a14
May ’25US$76.28
US$84.27
+10.5%
7.6%US$95.00US$70.00n/a15
Apr ’25US$76.12
US$82.67
+8.6%
7.6%US$95.00US$70.00n/a15
Mar ’25US$73.65
US$82.67
+12.3%
7.6%US$95.00US$70.00n/a15
Feb ’25US$74.41
US$81.39
+9.4%
7.5%US$95.00US$70.00n/a15
Jan ’25US$71.45
US$80.08
+12.1%
8.1%US$95.00US$70.00n/a16
Dec ’24US$71.15
US$79.83
+12.2%
8.5%US$95.00US$70.00US$79.5016
Nov ’24US$66.69
US$83.28
+24.9%
9.1%US$95.00US$70.00US$82.3315
Oct ’24US$69.40
US$88.33
+27.3%
8.1%US$95.00US$70.00US$80.5615
Sep ’24US$75.12
US$88.33
+17.6%
8.1%US$95.00US$70.00US$81.2415
Aug ’24US$76.61
US$88.80
+15.9%
8.1%US$98.00US$70.00US$83.2015
Jul ’24US$80.97
US$91.04
+12.4%
8.9%US$105.00US$70.00US$74.1014
Jun ’24US$79.15
US$91.04
+15.0%
8.9%US$105.00US$70.00US$73.7814
May ’24US$87.67
US$87.61
-0.07%
7.9%US$95.00US$70.00US$76.2814
Apr ’24US$80.70
US$86.04
+6.6%
8.5%US$95.00US$70.00US$76.1214
Mar ’24US$79.06
US$86.64
+9.6%
8.9%US$95.00US$70.00US$73.6514
Feb ’24US$82.78
US$82.36
-0.5%
8.6%US$91.00US$70.00US$74.4114
Jan ’24US$74.81
US$77.71
+3.9%
7.4%US$90.00US$70.00US$71.4514
Dec ’23US$76.99
US$77.25
+0.3%
7.3%US$90.00US$70.00US$71.1512

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:17
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2024/09/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hologic, Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays